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Abstract: Extraction of an impacted mandibular third molar is a
common surgical procedure, although it still leads to several
postoperative symptoms and complications. The study assessed
the efficacy of autologous plasma rich in growth factors (PRGF)
in the healing process by checking the difference of tissue cyto-
kines and other healing factors produced by the mucosa after
extraction between sites treated with PRGF and control sites
and, at the same time, by evaluating the clinical efficacy of PRGF
in terms of reduced pain and facial swelling. This study was a
split-mouth study, in which the patient becomes his/her own
control, to eliminate any individual response differences toward
PRGF treatment. The parameters regarding inflammation and
subsequent wound healing were all significantly higher at PRGF
sites than at control sites. The increase at PRGF sites of the two
proinflammatory cytokines evaluated, interleukin (IL)-1b and
IL-6, was accompanied by the increase of two anti-inflammatory
cytokines, IL-10 and transforming growth factor-b. Furthermore,
IL-1b and IL-6 induce fibroblast and keratinocyte proliferation,
important events in wound healing. Postoperative pain and the
swelling, measured at all experimental times, were reduced in
the presence of PRGF. VC 2010 Wiley Periodicals, Inc. J Biomed Mater
Res Part A: 95A: 741–746, 2010.
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INTRODUCTION
Extraction of an impacted mandibular third molar is a com-
mon procedure in oral and maxillofacial surgery. Despite
the development of new techniques and materials, this kind
of surgery still leads to several postoperative symptoms and
complications, with temporary alterations in the patient’s
quality of life. In the first week after surgery, pain, swelling,
and trismus are frequent symptoms, sometimes with
marked functional alteration. Alveolitis, infection, and hem-
orrhage are other common postoperative complications.1–4
To reduce the risk of complications, researchers and
clinicians are advancing rapidly toward treatments that
reduce morbidity while enhancing functional recovery. An
important example is the development of platelet-rich thera-
pies. The use of blood-derived products to seal wounds and
stimulate healing was first described by Kingsley,5 who
used an autologous platelet-derived preparation called pla-
telet-rich plasma (PRP) to promote/accelerate wound cica-
trization. The first application of an autologous fibrin glue
in oral surgery was reported in 1994 by Tayapongsak
et al.,6 who used autologous fibrin adhesive as a medium
for compacting grafts. The emergence and application of
these platelet-enriched preparations have revolutionized the
field of regenerative medicine, thanks to the repair capaci-
ties of the growth factors and other proteins secreted by
platelets.
In 1997, Whitman et al.7 used platelet gel in reconstruc-
tive maxillofacial surgery. Marx et al.8 was the first to stand-
ardize the technique for using PRP, a volume of autologous
plasma with a platelet concentration above baseline, acti-
vated by bovine thrombin and calcium chloride. The mono-
clonal antibody technique has revealed the presence of
transforming growth factor (TGF)-b1, TGF-b2, and platelet-
derived growth factor (PDGF) in PRP.7,8 In the last few
years, PRP has been widely used in oral surgery, alone or
with various graft materials, to accelerate and facilitate tis-
sue and bone regeneration.9 Anitua et al.10–13 introduced a
new protocol for platelet gel preparation, producing the so-
called plasma rich in growth factors (PRGF). PRGF is consid-
ered an optimized and safe product, which circumvents
many of the limitations entailed in the use of other PRPs.
For example, its preparation does not require large amount
of blood as does that of PRP, and it does not use exogenous
bovine thrombin as activator, obviating immunological reac-
tions and risk of disease transmission. These platelet gels
are highly concentrated forms of autogenous platelets,
known for their role in hemostasis, where they prevent
blood loss at sites of vascular injury. They do so by adher-
ing, aggregating, and forming a procoagulant surface leading
to thrombin generation and fibrin formation. Platelets also
release substances that promote tissue repair and influence
the reactivity of vascular and other blood cells in
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angiogenesis and inflammation. The alpha granules of plate-
lets contain storage pools of growth factors, including plate-
let-derived growth factor, vascular endothelial growth factor,
transforming growth factor-b, epidermal growth factor, insu-
lin-like growth factor, and fibroblast growth factor, as well
as extracellular matrix components, such as fibronectin,
thrombospondin, and vitronectin. Chemokines and newly-
synthesized active metabolites are also released. The fact
that platelets secrete growth factors and active metabolites
means that their applied use can have a positive influence
in clinical situations requiring rapid healing and tissue
regeneration.
The effect of local application of a scaffold-like prepara-
tion rich in growth factors (PRGF) was investigated: PRGF
has been shown to accelerate bone regeneration in artificial
defects and to improve the osseointegration of titanium
dental implants.14 Orthopedic surgery, muscle and/or ten-
don repair, treatment of joint diseases, reversal of skin
ulcers, and hole repair in eye surgery and cosmetic surgery
are other situations where autologous platelets accelerate
healing.11–13,15
The aim of this split-mouth study was to assess the effi-
cacy of autologous PRGF in the healing process after third
molar extraction. This was addressed by verifying the differ-
ence in tissue cytokines and other healing factors produced
by the mucosa after extraction between sites treated with
PRGF and control sites and, at the same time, by evaluating
the clinical efficacy of PRGF treatment. No studies, in partic-
ular not of the split-mouth type, have yet examined the pro-
duction of biological factors at sites treated with PRGF after
impacted third molar extraction while evaluating clinical as-
pect, such as pain and facial swelling.
MATERIALS AND METHODS
Sixteen healthy patients, aged 18 to 35 years (mean 22.5
years), with impaction of both lower third molars and indi-
cations to their extraction, entered the study. Patient selec-
tion was based on the absence of any local or systemic dis-
ease that might contraindicate the treatment. Informed
consent was obtained from all patients entering the study.
Preparation of PRGF
Blood was obtained several minutes before starting surgery,
prior to administration of anesthesia. Ten to twenty millili-
ters of blood were drawn from each patient using 5-mL
tubes, containing 3.8% trisodium citrate solution as anticoa-
gulant. The tubes were centrifuged at 1800 rpm for 8 min
(PRGF SistemVR , BTI Biotechnology Institute, Milan, Italy) at
room temperature. The blood was, thus, separated into its
three basic components: red blood cells, which appeared at
the bottom of the tube, PRGF in the middle of the tube, and
plasma poor in growth factors (PPGF) at the top of the
tube. The fraction (0.5 mL) located immediately above the
erythrocytes was collected from each tube and transferred
to sterile tubes. Calcium chloride (50 lL) at 10% was added
per 1-mL fraction of PRGF. After 15 to 20 min, a PRGF gel
was formed. The time delay between PRGF gel formation
and filling the defect was standardized to 5 to 10 min.
Surgical protocol
Both the mandibular third molars were extracted in the
same surgical session. After truncular and locoregional an-
esthesia (mepivacaine 2% with adrenaline 1:100,000), a
full-thickness mucoperiosteal flap was raised. Osteotomy
was first performed using a Lindeman burr in conjunction
with constant irrigation, followed by odontotomy and, if
necessary, tooth luxation and avulsion.
In each patient, one postextractive defect was filled with
PRGF whereas the other was left empty as control site. Left
and right sockets were assigned randomly. This provided
the best possible control group, because both treatments
were carried out in the same patient, with the same surgical
procedure and identical microbiologic conditions, and by
the same surgeon. In all cases, 3-0 silk sutures were used to
stitch the flap; they were removed after 7 days. Patients
were given antibiotic (amoxicillin every 12 h for 6 days)
and oral anti-inflammatory treatment (nimesulide every
12 h for 3 days).
Samples of soft tissues were removed from around the
tooth at the following times: before tooth extraction (T0)
and after 7 days (T7). All specimens were placed in RNA-
later solution (Qiagen, Milan, Italy), and maintained at
80C until use.
Biological factor analysis
The samples were processed to determine cytokines and
protein expression using real-time polymerase chain reac-
tion (PCR). The inflammatory cytokines interleukin (IL)-1b,
IL-6, IL-10, TGF-b2, bone morphogenetics protein (BMP)-4
and BMP-7, peroxisome proliferator-activated receptor
(PPAR)-b, and collagen type I and type III were examined.
Total ribonucleic acid (RNA) was extracted from the
specimens using the NucleoSpin RNA II Kit (Macherey-Nagel
GmbH & Co., KG, Du¨ren, Germany). Real-time PCR was per-
formed with single-stranded complementary deoxyribonu-
cleic acid (cDNA) prepared from total RNA (1 lg) using a
high-capacity cDNA archive kit (Applied Bio Systems, Foster
City, CA).
The forward (FW) and reverse (RV) primers listed in Ta-
ble I were designed using the Beacon DesignerV
R
program
(Bio-Rad, Hercules, CA). Twenty-five microliters of a PCR
mixture containing cDNA template equivalent to 40 ng of
total RNA, 5 pmoles each of FW and RW primers, and 2 
IQ SYBR Green SuperMix (Bio-Rad) were amplified using an
iCycler PCR instrument (Bio-Rad) with an initial melt at
95C for 10 min, followed by 35 to 40 cycles at 95C for 40
s, annealing temperature for each primer set for 40 s, and
72C for 40 s. A final extension of 7 min at 72C was
applied. Each sample was tested in duplicate, and threshold
cycle (Ct) values were averaged from each reaction. The fold
change, for both control and PRGF samples, was defined as
the relative expression in the sample removed 7 days after
the extraction of teeth (T7) compared with that in the sam-
ple removed before the extraction (T0), calculated as 2DDCt,
where DCt ¼ CtsampleCtGAPDH and DDCt ¼ DCtT7sample
DCtT0sample.
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Clinical evaluation
For the clinical examination, the patient was asked to score
his/her feeling of pain on a 10-cm visual analog scale (VAS),
with 0 cm reflecting no pain and 10 cm reflecting worst
pain possible. The pain was evaluated each day at the same
hour from 2 h after extraction (T1) to day 7 (T7) in the
postoperative period. At the same time, the patient was
asked to measure facial swelling, with the exception of the
first and seventh measures, which were done by a dentist.
Facial swelling was evaluated using a horizontal and vertical
guide with a flexible ruler and a vernier caliper, and the
control points described by Neupert et al.16 The facial meas-
ures corresponded to mentalis angle (Go) and 4 facial
points indicating the angle of the mandible: (1) ear tragus
(Tr), (2) external canthal of the eye (Ca), (3) nose spine
(Sp), and (4) buccal commissure (Po). The facial swelling
score was obtained by dividing the measures made in the
postoperative period (day 2–7) by the value for the preop-
erative period (T0).
Statistical analysis
Statistical analyses were performed using InStat3 software.
All data are expressed as means 6 standard deviation (SD).
The significance of differences between control and PRGF
mean values was assessed by the nonparametric Wilcoxon
test. Data were statistically significant when p < 0.05.
As regards facial swelling, the collected data were ana-
lyzed using the Wilcoxon signed rank test. The level of sig-
nificance applied was 5.0%.
RESULTS
Sixteen healthy patients, aged between 18 and 35 years
with both impacted lower third molars requiring extraction,
comprised the study group. There was no significant differ-
ence between the two operations in each individual patient,
as regards duration of surgery and amount of local anes-
thetic administered.
Biological factor analysis
Figures 1–4 report the data relating to various biological
factors that are involved in the healing of wounds caused
by tooth extraction, and show the differences between the
PRGF site and control site. The data refer to T7 and were
compared with those obtained at T0, taken as 1 (black line
in the figures).
As shown in Figure 1, IL-1b, IL-6, and IL-10 increased at
the site treated with PRGF in comparison with the control
site at 7 days after extraction, the increase for IL-1b being
about five times the control value, IL-6 about three times
and IL-10 about twice. On the contrary, the increase of TGF-
TABLE I. Forward and Reverse Primers






GAPDH, NM_002046 FW 50-GTC GGA GTC AAC GGA TTT GG-30 52; 35 142
RV 50-GGG TGG AAT CAT ATT GGA ACA TG-30
IL-1b, AF043335 FW 50-GCA CCT TCT TTC CCT TCA TCT TT-30 52; 40 105
RV 50-GCG TGC AGT TCA GTG ATC GTA-30
IL-6, M14584 FW 50-CCA GTA CCC CCA GGA GAA GAT T-30 52; 40 78
RV 50-GTC AAT TCG TTC TGA AGA GGT GAG T-30
IL-10, AY029171 FW 50-CCG AGA TGC CTT CAG CAG AG-30 60; 30 154
RV 50-CAT CAC CTC CTC CAG GTA AAA CT-30
TGF-b2, NM_003238 FW 50- GAG TAC TAC GCC AAG GAG GTT TAC A-30 52; 40 104
RV 50-CGA ACA ATT CTG AAG TAG GGT CTG T-30
BMP-4, D30751 FW 50-CTC GCT CTA TGT GGA CTT C-30 58; 40 130
RV 50-ATG GTT GGT TGA GTT GAG G-30
BMP-7, NM_001719 FW 50-GTG GAA CAT GAC AAG GAA T-30 58; 40 65
RV 50-GAA AGA TCA AAC CGG AAC-30
PPAR-b, XM_165760 FW 50-AAA GAA GGC CCG CAG CAT-30 56; 40 170
RV 50-CTG GAT GTC GTG GAT CAC AAA-30
Collagen type I, NM_000089 FW 50-GAG GAA ACT GTA AGA AAG G-30 58; 35 150
RV 50-GTT CCC ACC GAG ACC-30
Collagen type III, NM_000090 FW 50-ACT CGC CCT CCT AAT GG-30 59; 35 148
RV 50-GGC ATG ATT CAC AGA TTC C-30
FIGURE 1. IL-1b, IL-6, and IL-10 values in PRGF and control sites at
T7. Control and PRGF values at T7 are compared with their respective
T0 values (black line). The values are means 6 SD of 16 patients. The
significance of differences between control and PRGF means was
assessed by nonparametric Wilcoxon test (*p < 0.05 PRGF vs.
control).
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b2 (Fig. 2), as also that of BMP-4 and BMP-7 (Fig. 3), at
sites treated with PRGF in comparison with control sites,
was lower that the increase in ILs, being about 1.30, 1.20,
and 1.5 times for TGF-b2, BMP-4, and BMP-7, respectively.
For PPAR-b, no increase was observed.
Collagen I and III (Fig. 4) increased at sites treated with
PRGF in comparison with the control sites, as occurred in
the case of cytokines, the increase for collagen I (3.6 times
the control value) being greater than that for collagen III
(3 times the control value). Comparing the changes in col-
lagen I and III, the latter was changed more than the for-
mer: 12 versus 7.
Clinical evaluation
The VAS of pain was lower for PRGF sited than for control
sites at all times examined, even if the difference was signif-
icant only at T7 (Fig. 5).
Figure 6 shows the difference in facial swelling between
PRGF sites and control sites. At the PRGF sites, there was
less swelling than at the control sites; the difference was
significant for all the four measures, Go-Ca, Go-Tr, Go-Po,
and for Go-Sp, with the exception of time T7 for Go-Tr and
Go-Po.
DISCUSSION
Surgery of impacted third molars is one of the most fre-
quent procedures in oral and maxillofacial surgery1–4 and
can lead to immediate postoperative pain and discomfort.1–4
Trismus is a direct sequel of postoperative swelling, which
can compress nerve structures and generate mild to severe
pain.17,18 Thus, it appeared that, in addition to the use of
analgesics, PRGF might improve wound healing after third
molar extraction and, at the same time, reduce pain and
swelling. A significant problem with this experimental
approach is designing appropriate control groups. To avoid
this problem, this study employed a ‘‘split-mouth’’ method,
whereby one side of each patient was included in the con-
trol group, and the other side (randomly selected) was in
the PRGF group. In this model of split-mouth study, the
patient becomes his/her own control, to eliminate any indi-
vidual response differences toward PRGF treatment.
The parameters regarding the inflammation process and
subsequent wound healing were all significantly higher at
FIGURE 2. TGF-b2 and PPAR-b values in PRGF and control sites at T7.
Control and PRGF values at T7 were compared with their respective
T0 values (black line). The values are means 6 SD of 16 patients. The
significance of differences between control and PRGF means was
assessed by nonparametric Wilcoxon test (*p < 0.05 PRGF vs.
control).
FIGURE 3. BMP-4 and BMP-7 values in PRGF and control sites at 7
days after surgery. Control and PRGF values at 7 days were compared
with their respective T0 values (black line). The values are means 6
SD of 16 patients. The significance of differences between control and
PRGF means was assessed by nonparametric Wilcoxon test. (*p <
0.05 PRGF vs. control).
FIGURE 4. Collagen I and III values in PRGF and control sites at 7
days after surgery. Control and PRGF values at 7 days were compared
with the respective T0 values (black line). The values are means 6 SD
of 16 patients. The significance of differences between control and
PRGF means was assessed by nonparametric Wilcoxon test (*p <
0.05 PRGF vs. control).
FIGURE 5. VAS for pain measurement in PRGF and control sites. Val-
ues are means 6 SD of 16 patients. The significance of differences
between control and PRGF means was assessed by nonparametric
Wilcoxon test (*p < 0.05 PRGF vs. control).
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PRGF sites than at control sites. It might seem surprising
that inflammation parameters, such as IL-1b and IL-6, were
found at higher levels at PRGF sites than at control sites.
Two possible explanations can be done: 1. IL-1b and IL-6
could facilitate wound healing, as demonstrated by the
increase in collagen I and III. In fact, in addition to its prin-
cipal pro-inflammatory activity, IL-1b can also stimulate
fibroblast proliferation, collagen synthesis and the produc-
tion of collagenases, implicated in collagen remodeling dur-
ing wound healing.19 IL-6 also shows slight anti-inflamma-
tory activity,20 inducing keratinocyte proliferation and
inhibiting pro-inflammatory cytokines.21 Thus the involve-
ment of IL-1b and IL-6 on facilitating wound healing must
be also considered as a possibility, based on their stimula-
tion of fibroblast and keratinocyte proliferation. 2. At the
PRGF sites, the increase of IL-1b and IL-6 was also accom-
panied by the increase in IL-10 and TGF-b2, two cytokines
possessing anti-inflammatory activity and inducing fibro-
blast proliferation.19 Therefore, IL-10 and TGF-b2 could pre-
vent the pro-inflammatory properties of IL-1b and IL-6,
favoring the healing process.
In parallel to the inflammation and healing parameters,
pain and swelling were measured at all experimental times.
Pain was measured by VAS scale, a relatively simple method
for pain measurement, because experimental subjects can
easily reply to the question.22 Postoperative swelling was
measured using the method of Neupert et al.16 Both meas-
ures showed that PRGF reduces postoperative pain and
swelling. As regards the first parameter, severe pain was
experienced 2 h after surgery at which time the mean VAS
pain score was 4.03 cm at control sites and 3.54 cm at
PRGF sites. This represents a 12.16% reduction, which is
less than that reported by other researchers as being a clini-
cally significant reduction.23 The difference between the two
sites persisted until 7 days after surgery, when the mean
VAS pain score was 0.49 cm at control sites and 0.19 cm at
PRGF sites. This represents a 61.22% reduction and is
highly significant.
Facial swelling, evaluated with different measures, was
demonstrated to be reduced at PRGF sites compared with
control sites. For Go-Tr and Go-Po, the difference disap-
peared at the end of the experimental time, whereas it
remained for Go-Ca and Go-Sp.
In conclusion, this study employed a viable and simple
method to evaluate the action of PRGF and its effect on
inflammation process, wound healing, pain, and swelling sci-
entifically, without enrolling a placebo control group. PRGF
was found to be more effective on all parameters examined.
Thus, it may be used on a routine basis after third molar
surgery, without any associated side effects.
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